A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a world-wide pandemic. Internationally, because of availability, accessibility, and distribution issues, there is a need for additional vaccines. This study aimed to: establish the feasibility of personal dendritic cell vaccines...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Gabriel I. Nistor, Robert O. Dillman, Rockelle M. Robles, James L. Langford, Aleksandra J. Poole, Muchlis A. U. Sofro, Yetty M. Nency, Jonny Jonny, Martina L. Yana, Mahammad Karyana, Endang S. Lestari, Ria Triwardhani, Mujahidah Mujahidah, Retty K. Sari, Nur A. Soetojo, Djoko Wibisono, Daniel Tjen, Taruna Ikrar, Gregory Sarkissian, Haryono Winarta, Terawan A. Putranto, Hans S. Keirstead
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-11-01
Subjects:	personal vaccine sars-cov-2 phase 1 phase 2 dendritic cells
Online Access:	http://dx.doi.org/10.1080/21645515.2022.2100189